1 Jordan Pickford is being targeted by a host of England’s biggest clubs Sunderland boss David Moyes has warned Jordan Pickford’s suitors not to expect a fire-sale price after confirming the club will only consider offers of around £30million.The 23-year-old goalkeeper has enjoyed a stunning season for the relegated Black Cats, also earning a call-up to the senior England squad, and is being eyed by several potential buyers.Everton are reportedly the latest, but Moyes said: “It would need to be a really, really big offer.“I have said all through the season that sometimes on your journey, you may have to sell to improve.“But I have heard some really derisory sort of figures getting mentioned, and it wouldn’t be any of those figures, I can tell you that.”Asked if the Washington-born keeper’s price tag would be in the region of £30million, Moyes replied: “Yes.”
The company said it expects to submit five new products to government regulators for review in the next four years as it seeks new indications for existing products. It plans to submit an application for Arxxant, a drug to prevent blindness caused by diabetes, to regulators by the end of February. Some analysts were expecting a submission later this year but don’t believe the delay is significant. Another drug that has piqued analysts’ interest is blood thinner Prasugrel, which the company expects to submit in 2007. Analysts agree Prasugrel has blockbuster potential. Lilly also said it plans to reduce the average development cost for new drugs by one-third, to $800 million from $1.2 billion by the end of the decade. Lilly shares rose $1.20, or 2.3 percent, to close at $53.41 Friday on the New York Stock Exchange. NEW YORK – Drug maker Eli Lilly and Co. on Friday said it would post earnings per share at the high end of its forecast for this year, and its estimates for next year topped analysts’ projections. Its share price rose more than 2 percent in late trading. The company said, excluding items, it expects to come in at the top of its earnings outlook of $2.80 to $2.86 per share for 2005. Including a charge to settle a product-liability dispute in the second quarter for its anti-psychotic medication Zyprexa, the company expects full-year earnings per share at the high end of a $1.90 to $1.96 range. For 2006, the company forecast earnings per share of $3.10 to $3.20 excluding items. Analysts surveyed by Thomson Financial predicted earnings of $3.08 in 2006. 160Want local news?Sign up for the Localist and stay informed Something went wrong. Please try again.subscribeCongratulations! You’re all set!